BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malik A, Kardashian AA, Zakharia K, Bowlus CL, Tabibian JH. Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. Liver Res 2019;3:118-27. [PMID: 32042471 DOI: 10.1016/j.livres.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Yang H, Luo F, Wei Y, Jiao Y, Qian J, Chen S, Gong Y, Tang L. TGR5 protects against cholestatic liver disease via suppressing the NF-κB pathway and activating the Nrf2/HO-1 pathway. Ann Transl Med 2021;9:1158. [PMID: 34430599 DOI: 10.21037/atm-21-2631] [Reference Citation Analysis]
2 Ahmadi A, Niknahad H, Li H, Mobasheri A, Manthari RK, Azarpira N, Mousavi K, Khalvati B, Zhao Y, Sun J, Zong Y, Ommati MM, Heidari R. The inhibition of NFкB signaling and inflammatory response as a strategy for blunting bile acid-induced hepatic and renal toxicity. Toxicol Lett 2021;349:12-29. [PMID: 34089816 DOI: 10.1016/j.toxlet.2021.05.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]